Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04100109
Recruitment Status : Not yet recruiting
First Posted : September 24, 2019
Last Update Posted : November 19, 2019
Sponsor:
Information provided by (Responsible Party):
University of Minnesota

Brief Summary:
This study will evaluate the feasibility and obtain a preliminary estimate of efficacy of feeding 15 g/day of a new novel prebiotic dietary fiber, termed polylactose, in 40 children (8-12 years old) with obesity (body mass index [BMI]-percentile >/= 95th) who have magnetic resonance imaging (MRI)-confirmed non-alcoholic fatty liver disease [NAFLD] (hepatic fat fraction >/= 5.5%), compared to a placebo of 15 g/d of cellulose, an inert dietary fiber.

Condition or disease Intervention/treatment Phase
Obesity, Adolescent Obesity, Childhood Dietary Supplement: Polylactose Other: Placebo Not Applicable

Detailed Description:

Approximately 13% of all children (2 - 19 years old) are afflicted with NAFLD with the prevalence of NAFLD increasing to 60-80% among youth with obesity. NAFLD is characterized by excessive deposition of fat in the liver, which is an independent risk factor for the development of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Unchecked, NAFLD can progress into more severe forms of liver disease, including NASH, cirrhosis, and hepatocellular carcinoma, which eventually can lead to liver transplantation or death. Unfortunately, treatment of NAFLD through lifestyle interventions is extremely challenging and minimally effective even under intensive conditions. Bariatric surgery has shown promise as a treatment approach in adults, but remains controversial for a treatment of NAFLD in pediatrics.Even if bariatric surgery is proven effective, the overall impact will be low since a very small proportion of adolescents with obesity opt for this extreme treatment. Moreover, surgery is not indicated in youth with milder forms of obesity or younger children and since NAFLD occurs across the entire age-spectrum and is not exclusive to youth with obesity, a large need would be unmet by surgical treatment options. Therefore, novel non-surgical approaches that complement lifestyle modification therapy are needed in order to advance the field in a meaningful way and to provide care to a wide-range of youth with NAFLD. However, no safe or effective pharmacotherapy treatment options are presently available for youth with NAFLD, leaving a tremendous gap in care. Therefore, altering the gut microbiome through administration of a prebiotic dietary fiber is an attractive treatment option.

To date, no medications have been successful at producing meaningful improvements in NAFLD among youth. Similarly, in adults, existing pharmacotherapy options elicit some improvement in liver enzymes and/or histology but have failed to demonstrate widespread efficacy. Moreover, most medications are not indicated for children under the age of 12, and pediatricians are adverse to using them until all other treatment options have failed. Therefore, alternative approaches must be taken in this difficult-to-treat clinical population to identify more effective treatment options. A prebiotic dietary fiber may offer a potential novel treatment option for NAFLD in children with obesity.

Subjects who are interested in participating in the study will be asked to come in for a screening visit where their parent will sign a parental consent form and the child will sign an assent form. Blood will be drawn for safety tests and biomarker sampling. Urine and stool will also be collected. A portable glucose monitor will be placed to collect timed glucose results. Subjects will have an MRI to confirm their NAFLD and their BMI will be calculated. Subjects will undergo a dual x-ray absorptiometry (iDXA) scan and lifestyle counseling. Subjects enrolled in this study will be randomly assigned (1:1) to receive either polylactose or the placebo. Subjects will take the polylactose or the placebo in foods provided by the study team (made in a food-grade space utilizing good manufacturing practices to minimize cross contamination). Subjects will take polylactose/placebo for 26 weeks. They will come have blood drawn for safety tests and biomarkers at weeks 8 and 26. They will have urine and stool samples collected at weeks 8, 20 and 26. Assessments of their glucose levels will be done via a wearable glucose monitor between the screening/randomization and week 4, and again between week 20 and week 26. MRI scans of the liver iDXA scans will be repeated at weeks 8 and 26. Lifestyle counseling and assessment of adverse events, compliance with taking the study product/placebo and tolerability of the intervention will take place at weeks 4, 8, 13, 20 and 26.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic
Estimated Study Start Date : February 1, 2020
Estimated Primary Completion Date : October 31, 2022
Estimated Study Completion Date : October 31, 2023

Arm Intervention/treatment
Active Comparator: Polylactose
Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing polylactose
Dietary Supplement: Polylactose
Polylactose 15 g/day

Active Comparator: Placebo
Subjects randomized to this arm of the study will be asked to consume 15 grams/day of foods containing cellulose, which is an inert dietary fiber, and which will act as our placebo for this project.
Other: Placebo
Cellulose 15 g/day




Primary Outcome Measures :
  1. Change in hepatic fat fraction [ Time Frame: Subjects will have MR Spectroscopy at Baseline, Week 8 and Week 26 ]
    The primary efficacy endpoint for this study will be the change in hepatic fat fraction from baseline to week 26



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 8-12 years old
  • Diagnosis of obesity: BMI percentile >/= 95th (using age- and sex- based Center for Disease Control definitions) or BMI >/= 30 kg/m2
  • Elevated alanine aminotransferase (ALT) more than twice the upper limit of normal by gender (>/= 44 U/L for girls, >/= 50 U/L for boys) within 6 months prior to screening or diagnosis of NAFLD from ultrasound or MRI within 6 months of screening or participants with biopsy-proven NASH within 12 months of screening

Exclusion Criteria:

  • ALT > 250 U/L at screening
  • History of significant alcohol intake or current use
  • Impaired fasting glucose (> 100 mg/dL)
  • Diabetes (type 1 or 2)
  • Current or recent (< 60 months prior to enrollment) use of weight loss medication(s)
  • Vitamin E supplementation
  • Previous bariatric surgery
  • Use of metformin
  • Metal or magnetic implants, devices or objects inside of or on the body, which are not MRI compatable
  • Recent initiation (< 3 months prior to enrollment) of anti-hypertensive or lipid medication(s)
  • Known hypothalamic or pituitary dysfunction
  • Tobacco use
  • Gilbert's syndrome
  • Any known causes of liver disease (except NAFLD and NASH)
  • Significant renal dysfunction as calculated by estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m2
  • Diagnosed monogenic obesity
  • History of cancer
  • Untreated thyroid disorder
  • Current or recent (< 6 months prior to enrollment) use of medication(s) associated with weight gain (e.g. atypical anti-psychotics)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04100109


Contacts
Layout table for location contacts
Contact: Justin Ryder, PhD (612)625-3893 jrryder@umn.edu

Sponsors and Collaborators
University of Minnesota
Investigators
Layout table for investigator information
Principal Investigator: Justin Ryder, PhD University of Minnesota

Layout table for additonal information
Responsible Party: University of Minnesota
ClinicalTrials.gov Identifier: NCT04100109    
Other Study ID Numbers: STUDY00007385
First Posted: September 24, 2019    Key Record Dates
Last Update Posted: November 19, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: The statistical analysis plan and the clinical study report may be shared with other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity
Pediatric Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms